Biomatrica Announce Marketing Agreement with QIAGEN
News Jun 07, 2007
The agreement provides QIAGEN with exclusive marketing rights for Biomatrica’s existing products for the storage of purified DNA beginning June, 2008. SampleMatrix® DNA storage products will continue to be available directly from Biomatrica for the next year.
Biomatrica’s SampleMatrix® products make it possible for scientists to store and ship purified DNA and cell samples at room temperature. Retrieval of DNA is simple; just add water. All samples are ready for use in any downstream application such as PCR, transformation, transfection, sequencing, genotyping, STR analysis, etc.
In addition, the product offering includes affordable sample management software, providing scalable solutions for customers in low and high-throughput laboratories and bio-banking databases.
“The strategic partnership with QIAGEN is the ideal arrangement to build Biomatrica’s innovative and cost effective products for DNA stabilization. The partnership combines Biomatrica’s know-how in biostabilization and manufacturing and QIAGEN’s marketing power to reach into all fields of the research and forensic communities,” said Judy Muller-Cohn Biomatrica’s Chief Executive Officer and co-founder.
“The Biomatrica-QIAGEN relationship gives Biomatrica’s products a stamp of approval from the market leader in quality DNA products,” said Rolf Muller, Biomatrica’s Chief Scientific Officer and co-founder. “It’s a powerful combination of innovation and credibility.”
"As evidenced by significant internal and partnered initiatives, QIAGEN sees significant value in a broad and deep portfolio in stabilization and storage solutions for biological samples. We are pleased to today announce a significant, synergistic expansion to our leadership position in this area,” said Peer M. Schatz, QIAGEN’s Chief Executive Officer.
Schatz continued: “The SampleMatrix® technology uses fascinating principles of nature for stabilizing biomolecules which then can be shipped and even stored at room temperature to be used in conjunction with a wide range of subsequent purification procedures and analytical processes. QIAGEN’s technology and marketing power, together with the development capabilities and know how and intellectual property rights of Biomatrica, provide the basis for a very strong, successful strategic partnership to market and develop products and methods which leverage QIAGEN’s sample technology and assay leadership”
During the course of the strategic partnership, Biomatrica’s SampleMatrix® technology and QIAGEN's exclusive rights are expected to be broadened to include the stabilization, shipping and storage of DNA molecules in blood and buccal swab samples for subsequent purification of the stabilized DNA for any kind of downstream application and for use in all markets. The existing and future products will be manufactured by Biomatrica and exclusively marketed and sold by QIAGEN.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.